Filter posts

The Challenges and Risks of Adopting Foreign Price Controls

The Trump Administration is moving forward with a plan to import foreign price controls into …

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest …

Why Are Patients Facing Higher Costs When They Go to the Pharmacy?

BIO is out with a new whiteboard video that explores why more and more patients …

Experts Weigh In on the Dangers of Importing Foreign Price Controls

Experts recently gathered on Capitol Hill to discuss how importing foreign price controls will lead …

“Health Care’s Big Spending Mismatch”

This week, Axios reported on new data that shows “the health care services that rack …

WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices

This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

A Few Questions as PBMs Have Their Day on Capitol Hill

Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in …

Dr. Emanuel Misses the Mark with Latest Industry Attack

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …